BUDGET IMPACT OF NIRAPARIB AS MAINTENANCE TREATMENT FOR MEDICARE PATIENTS WITH RECURRENT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

被引：0
|
作者：
Neeser, K. [1 ]
O'Neil, W. M. [1 ]
Stern, L. [1 ]
机构：
[1] Analyt Laser, New York, NY USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.129
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN51
引用
收藏
页码：S21 / S21
页数：1
相关论文
共 50 条
  • [41] Real-Life Data of Niraparib Maintenance Treatment in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 10 - 11
  • [42] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
    Vacheresse, Genevieve MacAulay
    Sabri, Elham
    Domingo, Sheryl
    Le, Tien
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [43] Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer
    Vacheresse, Genevieve Macaulay
    Le, Tien
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A194 - A194
  • [44] RESPONSE TO SUBSEQUENT PLATINUM-BASED CHEMOTHERAPY POST PARP INHIBITOR IN RECURRENT EPITHELIAL OVARIAN CANCER
    Vacheresse, Genevieve Macaulay
    Le, Tien
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 : A251 - A251
  • [45] Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment
    Ray-Coquard, Isabelle
    Mirza, Mansoor Raza
    Pignata, Sandro
    Walther, Axel
    Romero, Ignacio
    du Bois, Andreas
    CANCER TREATMENT REVIEWS, 2020, 90
  • [46] A randomized, double-blind phase III trial of niraparib maintenance treatment in patients with HRD plus advanced ovarian cancer after response to front-line platinum-based chemotherapy
    Gonzalez, A.
    Moore, K. N.
    Mirza, M. R.
    Vergote, I. B.
    Pothuri, B.
    Oza, A. M.
    Graybill, W. A.
    Yalcin, I.
    Agarwal, S.
    Monk, B. J.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 98 - 98
  • [47] Phase I study of combination chemotherapy with irinotecan and gemcitabine for taxane/platinum resistant ovarian, fallopian tube, or primary peritoneal cancer
    Yoshino, Kiyoshi
    Kamiura, Shoji
    Ogawa, Haruki
    Tokuhira, Atsushi
    Takemura, Masahiko
    Sawada, Kenjiro
    Ueda, Yutaka
    Mabuchi, Seiji
    Fujita, Masami
    Tsutsui, Tateki
    Kimura, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
    Musacchio, Lucia
    Salutari, Vanda
    Pignata, Sandro
    Braicu, Elena
    Cibula, David
    Colombo, Nicoletta
    Frenel, Jean Sebastien
    Zagouri, Flora
    Carbone, Vittoria
    Ghizzoni, Viola
    Giolitto, Serena
    Giudice, Elena
    Perri, Maria Teresa
    Ricci, Caterina
    Scambia, Giovanni
    Lorusso, Domenica
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (10) : 1369 - 1373
  • [49] Randomized phase III trial on niraparib - TSR-042 (dostarlimab) vs physician's choice CHEmotherapy in recurrent ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
    Lorusso, D.
    Musacchio, L.
    Pignata, S.
    Braicu, E. I.
    Cibula, D.
    Colombo, N.
    Frenel, J-S.
    Zagouri, F.
    Carbone, V.
    Ghizzoni, V.
    Giolitto, S.
    Giudice, E.
    Landolfo, C.
    Perri, M. T.
    Ricci, C.
    Salutari, V.
    Scambia, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S768 - S769
  • [50] A randomised Phase II study of phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer
    Goss, G.
    Quinn, M.
    Rutherford, T.
    Kelly, M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 261 - 261
12345